Purpose: In patients with non–small cell lung cancer (NSCLC), mutations in the epidermal
growth factor receptor (EGFR) tyrosine kinase domain have been associated with sensitivity …

Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been
detected in patients with non–small cell lung cancer (NSCLC) and are associated with …

A year has passed since mutations of the tyrosine kinase domain of the epidermal growth
factor receptor (EGFR) were discovered in patients with non–small cell lung cancer …

Purpose: Clinical reports about responsiveness to gefitinib treatment in patients of non-small
cell lung cancer (NSCLC) with mutations in exon 20 of epidermal growth factor receptor …

Aims Deletion of exon 19 of the epidermal growth factor receptor (EGFR) and mutation of
exon 21 are the most common EGFR mutations and predict higher response to EGFR …

Purpose: Mutations in epidermal growth factor receptor (EGFR) can be used to predict the
tumor response of patients receiving gefitinib for non–small cell lung cancer (NSCLC). We …

Background Activating mutations in the epidermal growth factor receptor gene (EGFR)
confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with …

Introduction: In non–small-cell lung cancer, an exon 19 deletion and an L858R point
mutation in the epidermal growth factor receptor (EGFR) are predictors of a response to …

Background There are many complex and rare mutations in the epidermal growth factor
receptor (EGFR) gene in non-small cell lung cancer (NSCLC) other than the two classical …

PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) gene are associated
with increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR …